Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 4/20 | 0.36 |
| ▸ | ACHE | P22303 | 8/20 | 0.36 |
| ▸ | BCHE | P06276 | 5/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 5/20 | 0.35 |
| ▸ | SUV39H1 | O43463 | 2/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.33 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.33 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20927487 | 1.00 | TACR1 (0.36) | TACR1ACHEBCHEEHMT2SUV39H1 | |
| SCHEMBL31672721 | 1.00 | TACR1 (0.36) | TACR1ACHEBCHEEHMT2SUV39H1 | |
| SCHEMBL29776833 | 1.00 | TACR1 (0.36) | TACR1ACHEBCHEEHMT2SUV39H1 | |
| SCHEMBL19655969 | 1.00 | TACR1 (0.36) | TACR1ACHEBCHEEHMT2SUV39H1 | |
| SCHEMBL19656075 | 1.00 | TACR1 (0.36) | TACR1ACHEBCHEEHMT2SUV39H1 | |
| SCHEMBL19657100 | 1.00 | TACR1 (0.36) | TACR1ACHEBCHEEHMT2SUV39H1 | |
| SCHEMBL30338080 | 1.00 | TACR1 (0.36) | TACR1ACHEBCHEEHMT2SUV39H1 | |
| SCHEMBL20927482 | 1.00 | TACR1 (0.36) | TACR1ACHEBCHEEHMT2SUV39H1 | |
| SCHEMBL20927481 | 0.99 | ACHE (0.36) | TACR1ACHEBCHEEHMT2SUV39H1 | |
| SCHEMBL20508875 | 0.99 | ACHE (0.36) | TACR1ACHEBCHEEHMT2SUV39H1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355596-A1 | COMPOSITIONS AND METHODS OF USING NMDAR INHIBITORS AND KINASE INHIBITORS TO TREAT LIVER CANCER | VERSITECH LIMITED (CN) | 2023-11-09 | — | — | US | claimed |
| EP-3560484-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G.L. Pharma GmbH (AT) | 2019-10-30 | — | — | EP | claimed |
| EP-3423034-B1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G L PHARMA GMBH (AT) | 2019-07-10 | — | — | EP | claimed |
| EP-3423034-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G.L. Pharma GmbH (AT) | 2019-01-09 | — | — | EP | claimed |
| CN-109069419-A | Abuse resistant drugs composition | G.L.制药有限责任公司 | 2018-12-21 | — | — | CN | claimed |
| EP-3210596-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G.L. Pharma GmbH (AT) | 2017-08-30 | — | — | EP | claimed |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2026-03-05 | — | — | US | disclosed |
| US-12527770-B2 | Methods of managing pain using dexmedetomidine transdermal delivery devices | TEIKOKU PHARMA USA, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250366979-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250366978-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| US-12485115-B2 | Biased NMDA receptor modulators and uses thereof | EDWARD Via COLLEGE OF OSTEOPATHIC MEDICINE (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4619763-A1 | BIOMARKER PANEL FOR BRAIN SPECIFIC ABNORMAL NEUROLOGICAL CONDITIONS USING BIOFLUID SAMPLES | Gryphon Bio, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250251323-A1 | COLLECTION PROBE AND METHODS OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE | 2025-08-07 | — | — | US | disclosed |
| EP-2443461-A2 | BIOMARKER ASSAY OF NEUROLOGICAL CONDITION | Banyan Biomarkers, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| CN-102223791-A | Topical formulations for treatment of neuropathy | TARAXOS INC | 2011-10-19 | — | — | CN | disclosed |
| US-20110178177-A1 | TOPICAL FORMULATIONS FOR TREATMENT OF NEUROPATHY | TARAXOS INC. (US) | 2011-07-21 | — | — | US | disclosed |
| EP-2334176-A1 | TOPICAL FORMULATIONS FOR TREATMENT OF NEUROPATHY | Taraxos Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2011011334-A2 | SYNERGISTIC BIOMARKER ASSAY OF NEUROLGICAL CONDITION USING S-100β | BANYAN BIOMARKERS, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010148391-A2 | BIOMARKER ASSAY OF NEUROLOGICAL CONDITION | BANYAN BIOMARKERS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010036937-A1 | TOPICAL FORMULATIONS FOR TREATMENT OF NEUROPATHY | TARAXOS INC. (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355596-A1 | COMPOSITIONS AND METHODS OF USING NMDAR INHIBITORS AND KINASE INHIBITORS TO TREAT LIVER CANCER | GRIN1, GRIN3A, GRIN3B | TACR1 2324/4885ACHE 1374/4885BCHE 1113/4885 |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | PFKP, PBK, MYLK | TACR1 4182/4885ACHE 1620/4885BCHE 804/4885 |
| US-12527770-B2 | Methods of managing pain using dexmedetomidine transdermal delivery devices | OPRD1, OPRK1, OPRM1 | TACR1 182/4885ACHE 660/4885BCHE 3201/4885 |
| US-12485115-B2 | Biased NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | TACR1 82/4885ACHE 681/4885BCHE 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.